Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Guo, Bao Hong ^a,b   Feng, Yan ^a   Zhang, Rong ^a   Xu, Li Hua ^a   Li, Man Zhi ^a   Kung, Hsiang Fu ^b   Song, Li Bing ^a   Zeng, Mu Sheng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; BMI1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NUCLEAR PROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL MOTILITY; CELL TRANSFORMATION; CORRELATION ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; LUNG METASTASIS; METASTASIS; NASOPHARYNX; NASOPHARYNX CANCER; NUDE MOUSE; PROTEIN EXPRESSION; SURVIVAL; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; FEMALE; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

GASTROPODA; MOLONEY MURINE LEUKEMIA VIRUS; MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79251589918     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-10     Document Type: Article

References (86)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63(1):181-7. 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H, 2910416.
3. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. The New England journal of medicine 2000, 342(8):525-33. 10.1056/NEJM200002243420801, 10684910.
4. Zhang L, Sullivan P, Suyama J, Marchetti D. Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res 2010, 8(2):278-90. 10.1158/1541-7786.MCR-09-0375, 20164500.
5. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 2010, 107(8):3698-703. 10.1073/pnas.0914203107, 2840447, 20133671.
6. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco MM, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 2010, 107(3):1100-5. 10.1073/pnas.0912710107, 2824265, 20080567.
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-52. 10.1038/35021093, 10963602.
8. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-9.
9. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001, 10(7):657-62. 10.1093/hmg/10.7.657, 11257096.
10. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009, 9(11):773-84. 10.1038/nrc2736, 19851313.
11. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65(5):753-63. 10.1016/0092-8674(91)90383-A, 1904009.
12. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65(5):737-52. 10.1016/0092-8674(91)90382-9, 1904008.
13. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer research 2002, 62(16):4736-45.
14. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423(6937):255-60. 10.1038/nature01572, 12714970.
15. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004, 13(5):383-8. 10.1016/j.breast.2004.02.010, 15454193.
16. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115(6):1503-21. 10.1172/JCI23412, 1136989, 15931389.
17. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, Lorenzo Y, Hurtado A, Sánchez A, Bonilla F. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 2007, 9(4):R55. 10.1186/bcr1760, 2206731, 17711569.
18. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer 2010, 102(2):369-75. 10.1038/sj.bjc.6605488, 2816658, 20010944.
19. Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK, Lee SJ, Kong G, Lee JE, Kim JS, Kim JH, Yang JH, Nam SJ. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast cancer research and treatment 2009, 113(1):83-93. 10.1007/s10549-008-9909-4, 18228133.
20. Saeki M, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N. Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers. Int J Oncol 2009, 35(3):511-5.
21. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66(12):6225-32. 10.1158/0008-5472.CAN-06-0094, 16778197.
22. Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL, Peng ZH. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2009,
23. Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS, Huang KH. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008, 97(3):267-72. 10.1002/jso.20934, 18041745.
24. Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP, Guo WJ. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 2010, 9(1):40. 10.1186/1476-4598-9-40, 2842237, 20170541.
25. Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C, Storz M, Seifert B, Marino S, Schraml P, Dummer R, Moch H. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 2007, 121(8):1764-70. 10.1002/ijc.22891, 17597110.
26. Jiang Y, Su B, Meng X, Liu C, Liu B, Liu D, Fan Y, Yang H. Effect of siRNA-mediated silencing of Bmi-1 gene expression on HeLa cells. Cancer Sci 101(2):379-86. 10.1111/j.1349-7006.2009.01417.x, 19930157.
27. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, Band V, Band H, Shi QH, Zeng YX, Zeng MS. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009, 119(12):3626-36. 10.1172/JCI39374, 2786794, 19884659.
28. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009, 28(34):3022-32. 10.1038/onc.2009.165, 2733922, 19543317.
29. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007, 28(3):297-321. 10.1210/er.2006-0027, 17409287.
30. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent results in cancer research Fortschritte der Krebsforschung 2000, 157:55-81.
31. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nature reviews 2004, 4(6):448-56. 10.1038/nrc1370, 15170447.
32. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews 2002, 2(6):442-54. 10.1038/nrc822, 12189386.
33. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002, 3(3):155-66. 10.1038/nrm757, 11994736.
34. Behrens J, Lowrick O, Klein-Hitpass L, Birchmeier W. The E-cadherin promoter: functional analysis of a G.C-rich region and an epithelial cell-specific palindromic regulatory element. Proceedings of the National Academy of Sciences of the USA 1991, 88(24):11495-9. 10.1073/pnas.88.24.11495, 53162, 1763063.
35. Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999, 18(51):7274-9. 10.1038/sj.onc.1203336, 10602481.
36. Giroldi LA, Bringuier PP, de Weijert M, Jansen C, van Bokhoven A, Schalken JA. Role of E boxes in the repression of E-cadherin expression. Biochemical and biophysical research communications 1997, 241(2):453-8. 10.1006/bbrc.1997.7831, 9425291.
37. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, García De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2(2):84-9. 10.1038/35000034, 10655587.
38. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 2(2):76-83. 10.1038/35000025, 10655586.
39. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6(10):931-40. 10.1038/ncb1173, 15448698.
40. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21(20):3241-6. 10.1038/sj.onc.1205416, 12082640.
41. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 2001, 20(29):3814-23. 10.1038/sj.onc.1204505, 11439345.
42. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006, 12(18):5395-402. 10.1158/1078-0432.CCR-06-0478, 17000672.
43. Takkunen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A, Virtanen I. Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. J Histochem Cytochem 2006, 54(11):1263-75. 10.1369/jhc.6A6958.2006, 16899764.
44. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 2009, 119(9):2678-90. 10.1172/JCI37815, 2735914, 19726885.
45. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15(5):402-15. 10.1016/j.ccr.2009.03.017, 19411069.
46. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010, 126(11):2575-83.
47. Cowell JK, LaDuca J, Rossi MR, Burkhardt T, Nowak NJ, Matsui S. Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. Cancer genetics and cytogenetics 2005, 163(1):23-9. 10.1016/j.cancergencyto.2005.04.019, 16271952.
48. Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 1978, 14(11):911-5. 10.1007/BF02616120, 730202.
49. Kremer M, Quintanilla-Martinez L, Fuchs M, Gamboa-Dominguez A, Haye S, Kalthoff H, Rosivatz E, Hermannstädter C, Busch R, Höfler H, Luber B. Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis. Carcinogenesis 2003, 24(12):1879-86. 10.1093/carcin/bgg148, 12949051.
50. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, Dimri GP. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007, 67(11):5083-9. 10.1158/0008-5472.CAN-06-4368, 2386662, 17545584.
51. Guo WJ, Datta S, Band V, Dimri GP. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Molecular biology of the cell 2007, 18(2):536-46. 10.1091/mbc.E06-05-0447, 1783768, 17151361.
52. Gong Y, Wang X, Liu J, Shi L, Yin B, Peng X, Qiang B, Yuan J. NSPc1, a mainly nuclear localized protein of novel PcG family members, has a transcription repression activity related to its PKC phosphorylation site at S183. FEBS letters 2005, 579(1):115-21. 10.1016/j.febslet.2004.11.056, 15620699.
53. Noguchi K, Shiurba R, Higashinakagawa T. Nuclear translocation of mouse polycomb m33 protein in regenerating liver. Biochemical and biophysical research communications 2002, 291(3):508-15. 10.1006/bbrc.2002.6480, 11855817.
54. Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes & development 1997, 11(2):226-40.
55. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, Kajiguchi T, Seto M, Kohno A, Kitamura K, Itoh Y, Asou N, Hamajima N, Emi N, Naoe T. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005, 82(1):42-7. 10.1532/IJH97.05013, 16105758.
56. Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006, 107(1):305-8. 10.1182/blood-2005-06-2393, 16160010.
57. Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE, Meijer CJ, Raaphorst FM, Smit EF. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 2005, 48(3):299-306. 10.1016/j.lungcan.2004.11.026, 15892997.
58. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004, 203(2):217-24. 10.1016/j.canlet.2003.07.009, 14732230.
59. Silva J, Garcia JM, Pena C, Garcia V, Dominguez G, Suarez D, Camacho FI, Espinosa R, Provencio M, España P, Bonilla F. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res 2006, 12(23):6929-36. 10.1158/1078-0432.CCR-06-0788, 17145810.
60. Miller WR. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. The Journal of steroid biochemistry and molecular biology. J Steroid Biochem Mol Biol 2010, 118(4-5):273-6. 10.1016/j.jsbmb.2009.10.005, 19837160.
61. Baumann CK, Castiglione-Gertsch M. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva ginecologica 2009, 61(6):517-39.
62. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360(8):790-800. 10.1056/NEJMra0801289, 19228622.
63. Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000, 92(21):1717-30. 10.1093/jnci/92.21.1717, 11058615.
64. Leuschner C, Enright FM, Gawronska B, Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast cancer research and treatment 2003, 78(1):17-27. 10.1023/A:1022169525521, 12611453.
65. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer research 1990, 50(3):717-21.
66. Goldson TM, Vielhauer G, Staub E, Miller S, Shim H, Hagedorn CH. Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells. Molecular carcinogenesis 2007, 46(1):71-84. 10.1002/mc.20276, 17091471.
67. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003, 4(8):657-65. 10.1038/nrm1175, 12923528.
68. Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T, Schreiber M, Jechlinger M, Beug H. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell 2006, 10(3):227-39. 10.1016/j.ccr.2006.07.020, 16959614.
69. Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, Seruca R, Schmitt FC, Paredes J. Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene 2009, 29(3):392-402. 10.1038/onc.2009.338, 19901964.
70. Denk C, Hulsken J, Schwarz E. Reduced gene expression of E-cadherin and associated catenins in human cervical carcinoma cell lines. Cancer letters 1997, 120(2):185-93. 10.1016/S0304-3835(97)00308-X, 9461036.
71. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature reviews 2004, 4(2):118-32. 10.1038/nrc1276, 14964308.
72. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. The Journal of clinical investigation 2004, 114(5):720-8. 514583, 15343391.
73. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7):927-39. 10.1016/j.cell.2004.06.006, 15210113.
74. Reichmann E, Schwarz H, Deiner EM, Leitner I, Eilers M, Berger J, Busslinger M, Beug H. Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 1992, 71(7):1103-16. 10.1016/S0092-8674(05)80060-1, 1473147.
75. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer research 2003, 63(9):2172-8.
76. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer research 2007, 67(7):3106-16. 10.1158/0008-5472.CAN-06-3401, 17409417.
77. Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. The Journal of pathology 1993, 169(2):245-50. 10.1002/path.1711690211, 8383197.
78. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003, 5(6):R217-22. 10.1186/bcr651, 314411, 14580257.
79. Bukholm IK, Nesland JM, Borresen-Dale AL. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. The Journal of pathology 2000, 190(1):15-9. 10.1002/(SICI)1096-9896(200001)190:1<15::AID-PATH489>3.0.CO;2-L, 10640987.
80. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer research 2001, 61(2):489-92.
81. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24(50):7455-64. 10.1038/sj.onc.1209085, 16288292.
82. Bernards R, Weinberg RA. A progression puzzle. Nature 2002, 418(6900):823. 10.1038/418823a, 12192390.
83. Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008, 61(2):197-203. 10.1136/jcp.2006.040378, 18223096.
84. Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Molecular and cellular biology 2000, 20(1):273-85. 10.1128/MCB.20.1.273-285.2000, 85083, 10594030.
85. Chung H, Jung JY, Cho SD, Hong KA, Kim HJ, Shin DH, Kim H, Kim HO, Shin DH, Lee HW, Jeong LS, Kong G. The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers. Mol Cancer Ther 2006, 5(3):685-92. 10.1158/1535-7163.MCT-05-0245, 16546983.
86. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and cellular biology 2004, 24(9):3992-4003. 10.1128/MCB.24.9.3992-4003.2004, 387763, 15082792.